Coronavirus Vaccine Nucleic Acid LNP Patent
Summary
USPTO published CureVac SE's patent application (US20260091107A1) for nucleic acid sequences and compositions suitable for coronavirus vaccines, particularly COVID-19, delivered via lipid nanoparticle (LNP) technology. The application covers compositions, vaccines, first and second medical uses, and methods of treatment or prevention. Filed as Application No. 19317057 with priority date September 2, 2025.
What changed
CureVac SE filed patent application US20260091107A1 claiming nucleic acid sequences and compositions for coronavirus vaccination, including compositions and vaccines comprising nucleic acid sequences in lipid nanoparticles (LNP). The application covers first and second medical uses of the nucleic acid, compositions, polypeptides, vaccines, combinations, and kits, as well as methods of treating or preventing coronavirus infections. Key CPC classifications include A61K 39/215 (coronavirus vaccines), A61K 9/0019 (lipid compositions), A61K 47/26 (lipid carriers), A61P 31/14 (antiviral agents), and A61P 37/04 (vaccines). The application names inventors Susanne Rauch, Hans Wolfgang Große, and Benjamin Petsch.
Patent clearance and freedom-to-operate review is recommended for competitors developing similar coronavirus vaccine technologies using LNP delivery systems. Parties should assess whether their products or pipeline candidates may fall within the scope of the claimed nucleic acid sequences and medical uses. The publication does not create immediate compliance obligations but establishes prior art that may affect future patent prosecution strategies.
What to do next
- Review application claims for potential freedom-to-operate concerns if developing similar LNP-based vaccine technology
- Assess whether existing or pipeline products may fall within the scope of CureVac's claimed nucleic acid sequences and medical uses
- Update IP portfolio strategy to account for this publication as prior art
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CORONAVIRUS VACCINE
Application US20260091107A1 Kind: A1 Apr 02, 2026
Assignee
CureVac SE
Inventors
Susanne RAUCH, Hans Wolfgang GROßE, Benjamin PETSCH
Abstract
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus Infection, preferably a Coronavirus infection.
CPC Classifications
A61K 39/215 A61K 9/0019 A61K 47/26 A61P 31/14 A61P 37/04 A61K 2039/53 A61K 2039/6018 A61K 2039/6093 A61K 2039/70
Filing Date
2025-09-02
Application No.
19317057
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Therapeutics (A61P) publishes new changes.